Lamivudine Completed Phase 1 Trials for Human Immunodeficiency Virus (HIV) Infections Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT01622790Evaluation of the Bioequivalence of a Combined Formulated Tablet
NCT02604004Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers